Patents Assigned to Universite Paris-Saclay
-
Patent number: 11692033Abstract: The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.Type: GrantFiled: February 2, 2018Date of Patent: July 4, 2023Assignees: Acticor Biotech, Université Paris Cité, Université Paris-XIII, Inserm (Institut National de la Santé et de la Recherche Médicale), Université Paris-SaclayInventors: Philippe Billiald, Martine Jandrot-Perrus, Gilles Avenard
-
Publication number: 20230203005Abstract: The present invention relates to the Compound of following formula (I): or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing such a compound and a method for preparing such a compound.Type: ApplicationFiled: March 6, 2023Publication date: June 29, 2023Applicants: UNIVERSITE PARIS-SACLAY, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT GUSTAVE-ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Mouad ALAMI, Olivier PROVOT, Abdallah HAMZE, Ilhem KHELIFI, Timothée NARET, Sébastien APCHER, Romain DARRIGRAND
-
Patent number: 11684640Abstract: The invention relates to gut microbiota profiles associated with response or resistance to treatments with ICB, in particular with anti-PD1 or anti PD-L1 or anti-PD-L2 antibodies. In particular, the invention pertains to a theranostic method for identifying good responders, to whom an anti-PD1 or anti PD-L1 or anti-PD-L2 can be administered, while a pre-treatment based on FMT and/or immunogenic probiotics is recommended to bad responders exhibiting a dysbiosis. In particular, the present invention pertains to Akkermansia muciniphila as the main commensal species distinguishing responders from progressors and its use alone or with E. hirae for the treatment of antibiotics or gut repertoire insufficiency-associated dysbiosis.Type: GrantFiled: December 22, 2017Date of Patent: June 27, 2023Assignees: INSTITUT GUSTAVE ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM, UNIVERSITE PARIS-SACLAY, Insitut national de recherche pour l'agriculture, l'alimentation et l'environnement (INRAE)Inventors: Laurence Zitvogel, Bertrand Routy, Emmanuelle Le Chatelier
-
Publication number: 20230190925Abstract: The present invention relates to phage T5 capsids that are devoid of genomic DNA from the phage and exposing, on their surface, at least one fusion protein of interest.Type: ApplicationFiled: September 18, 2020Publication date: June 22, 2023Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS-SACLAYInventors: Pascale BOULANGER, Emeline VERNHES, Nicolas DUCROT, Linda LARBI CHERIF, Karim BENIHOUD
-
Patent number: 11679148Abstract: The inventors provide a new therapeutic strategy to treat cancers expressing embryonic antigens. Accordingly, the present invention relates to a method of treating a subject suffering from a cancer comprising a step of administration simultaneously, separately or sequentially to said subject a therapeutically amount of i) a population of derived engineered fetal stem cells carrying cancer associated fetal neo-antigen and ii) a compound selected from a group which activates immune response, as a combined preparation.Type: GrantFiled: November 23, 2018Date of Patent: June 20, 2023Assignees: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS, UNIVERSITÉ PARIS-SACLAY, UNIVERSITÉ PARIS CITÉInventors: Frank Griscelli, Ali Turhan, Annelise Bennaceur Griscelli, Christophe Desterke
-
Publication number: 20230149405Abstract: A topical composition including erlotinib and a pharmaceutically acceptable excipient for use in the treatment of a keratoderma in a child, preferably a palmoplantar keratoderma (PPK), wherein the composition is topically administered. The composition may further include a penetration enhancer. The treated subject may be younger than three years old. Also, woven or non-woven fabric support including erlotinib and to dressings, patches, gloves and socks having the support useful in the treatment of a PPK.Type: ApplicationFiled: April 7, 2021Publication date: May 18, 2023Applicants: LABORATOIRES C.T.R.S., INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), FONDATION IMAGINE, UNIVERSITÉ PARIS CITÉ, UNIVERSITE PARIS-SACLAYInventors: Christine BODEMER, Céline GRECO, Claude BOUCHEIX, Jean-Pascal CONDUZORGUES, Joel SCHLATTER, Salvatore CISTERNINO
-
Patent number: 11642320Abstract: The present invention relates to anti-inflammatory drug formulation. Especially, this invention relates to corticosteroid prodrug nanoparticle. In a first aspect, this invention relates to a nanoparticle comprising a therapeutic agent and a surface coating material. The invention also relates to a process of manufacturing at least one nanoparticle of invention. The invention also relates to pharmaceutical composition and pharmaceutical kits.Type: GrantFiled: September 20, 2017Date of Patent: May 9, 2023Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS-SACLAYInventors: Elias Fattal, Nicolas Tsapis, Mathilde Lorscheider, Romain Canioni, Franceline Reynaud
-
Patent number: 11634405Abstract: The present invention relates to the Compound of following formula (I): or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing such a compound and a method for preparing such a compound.Type: GrantFiled: April 26, 2019Date of Patent: April 25, 2023Assignees: UNIVERSITE PARIS-SACLAY PARC TECHNOLOGIQUE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT GUSTAVE-ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Mouad Alami, Olivier Provot, Abdallah Hamze, Ilhem Khelifi, Timothée Naret, Sébastien Apcher, Romain Darrigrand
-
Patent number: 11590232Abstract: A bioconjugate comprising at least one neuropeptide covalently bond to at least one hydrocarbon compound of squalene structure.Type: GrantFiled: July 18, 2019Date of Patent: February 28, 2023Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS-SACLAYInventors: Patrick Couvreur, Jiao Feng, Sinda Lepetre-Mouelhi
-
Patent number: 11560436Abstract: The invention relates to isolated single-domain antibodies (sdAb) directed against von Willebrand Factor (VWF) D?D3 domain and chimeric polypeptides comprising thereof such as blood clotting factors and their uses in therapy such as in the prevention and treatment of hemostatic disorders. The invention also relates to a method of extending or increasing half-life of a therapeutic polypeptide comprising a step of adding to the polypeptide sequence of said therapeutic polypeptide at least one sdAb directed against VWF D?D3 domain.Type: GrantFiled: March 13, 2020Date of Patent: January 24, 2023Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS-SACLAYInventors: Petrus Lenting, Gabriel Ayme, Cecile Denis, Olivier Christophe
-
Patent number: 11551749Abstract: The present invention relates to a neuromimetic network comprising a set of neurons and a set of synapses, at least one neuron comprising a first stack of superimposed layers, the first stack successively comprising: a first electrode, a first barrier layer made of an electrically insulating material, and a second electrode, the first electrode, the first barrier layer and the second electrode forming a first ferroelectric tunnel junction, at least one synapse comprising a second stack of superimposed layers, the second stack successively comprising: a third electrode, a second barrier layer made of an electrically insulating material, and a fourth electrode, the third electrode, the second barrier layer and the fourth electrode forming a second ferroelectric tunnel junction.Type: GrantFiled: November 30, 2018Date of Patent: January 10, 2023Assignees: UNIVERSITE PARIS-SACLAY, THALES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Manuel Bibes, Julie Grollier, Vincent Garcia, Nicolas Locatelli
-
Publication number: 20230000801Abstract: A freeze-dried powder for preparing a thermogel including: from 1% to 35% of 2-[(3-aminopropyl)amino]ethanethiol or one of its pharmaceutically acceptable salt; from 40% to 85% of one or more poloxamer; and from 0.1% to 20% of one or more carbohydrate compound.Type: ApplicationFiled: November 24, 2020Publication date: January 5, 2023Applicants: CLEVEXEL PHARMA, INSTITUT GUSTAVE ROUSSY, UNIVERSITE PARIS-SACLAYInventors: Denis BRICOUT, Xiuping WANG-ZHANG, Eric DEUTSCH, Céline CLEMENSON
-
Publication number: 20220411846Abstract: A method for predicting the pathogenicity and virulence of a strain of Gram-negative bacteria of the Enterobacteriaceae family, wherein the amount of 2-hydroxymyristate and/or 2-hydroxymyristic acid present in the lipopolysaccharides of the bacteria is identified and measured, the amount of 2-hydroxymyristate and/or 2-hydroxymyristic acid is compared with a reference value, and wherein it is concluded that the strain is virulent if the amount of 2-hydroxymyristate is greater than the reference value. Also, the use of the 2-hydroxymyristic acid ester as a marker of pathogenicity and virulence of a Gram-negative bacterial strain and an in vitro diagnosis kit implementing this marker.Type: ApplicationFiled: November 19, 2020Publication date: December 29, 2022Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ PARIS-SACLAYInventors: Pierre TISSIERES, Luis AUGUSTO, Nadège BOURGEOIS-NICOLAOS, Richard CHABY, Aude BRETON, Florence DOUCET-POPULAIRE
-
Publication number: 20220383083Abstract: This method for training a binarized neural network, also called BNN, including neurons, with a binary weight for each connection between two neurons, is implemented by an electronic circuit and comprises: a forward pass including calculating an output vector by applying the BNN on an input vector; a backward pass including computing an error vector from the calculated output vector, and calculating a new value of the input vector by applying the BNN on the error vector; a weight update including computing a product by multiplying an element of the error vector with one of the new value of the input vector, modifying a latent variable depending on the product; and updating the weight with the latent variable; each weight being encoded using a primary memory component; each latent variable being encoded using a secondary memory component having a characteristic subject to a time drift.Type: ApplicationFiled: May 23, 2022Publication date: December 1, 2022Applicants: Commissariat à l'énergie atomique et aux énergies alternatives, Centre national de la recherche scientifique, UNIVERSITE PARIS-SACLAYInventors: Tifenn HIRTZLIN, Damien QUERLIOZ, Elisa VIANELLO
-
Patent number: 11458194Abstract: The inventors have developed a metastatic 4T1 breast tumor model in BALB/c mice. They have shown that the vaccination with xenogeneic embryonic stem cells in combination with valproic acid (VPA) generates a higher anti-tumoral response against breast cancer and inhibits metastasis development. They established that these responses are achieved only by the addition of valproic acid in the therapeutic regimen in comparison to the use ESCs or iPSCs alone. Thus, the inventors provide a new therapeutic strategy to treat cancers expressing embryonic antigens. Accordingly, the present invention relates to i) a population of pluripotent cells and ii) a compound selected from a group which activates MHC expression, as a combined preparation for use in a method for treating a subject suffering from a cancer, comprising a step of administering simultaneously, separately or sequentially to said subject a therapeutically amount thereof.Type: GrantFiled: May 24, 2017Date of Patent: October 4, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP), UNIVERSITE PARIS-SACLAY, UNIVERSITE PARIS CITEInventors: Frank Griscelli, Ali Turhan, Annelise Bennaceur Griscelli
-
Publication number: 20220175961Abstract: A recombinant adeno-associated virus (AAV) vector that carries a nucleic acid sequence encoding the retinal transcription factor cone-rod homeobox (CRX) for its use in treating CRX-associated IRDs in a subject in need thereof or for use in treating inherited retinal dystrophies caused by hypomorphic mutations in the CRX target genes.Type: ApplicationFiled: March 9, 2020Publication date: June 9, 2022Applicants: UNIVERSITE PARIS-SACLAY, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, RETINA FRANCE, VARIANTInventors: Jérôme ROGER, Elodie Kim GRELLIER
-
Patent number: 11344586Abstract: The present invention provides methods for determining if a patient is likely to benefit from a cancer treatment, by determining if said patient has a gut dysbiosis with an over representation of certain bacterial species. The present invention also provides probiotic strains to improve the efficacy of a cancer treatment, especially chemotherapy, in patients in need thereof.Type: GrantFiled: April 21, 2020Date of Patent: May 31, 2022Assignees: INSTITUT GUSTAVE ROUSSY, UNIVERSITE PARIS-SACLAY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENTInventors: Laurence Zitvogel, Ivo Gomperts Boneca, Patricia Lepage, Sophie Viaud, Romain Daillere
-
Publication number: 20220162266Abstract: The present invention relates to a mutant polypeptide comprising the amino acid sequence of the ectodomain of glycoprotein G of a vesicular stomatitis vims (VSV) strain, wherein said ectodomain comprises the amino acid sequence as set forth in SEQ ID NO: 2 or a sequence having at least 50% of identity with the amino acid sequence as set forth in SEQ ID NO: 2, with at least one substitution of an amino acid residue selected from the group consisting of: a) any amino acid residue located from position 421 to position 429 and any amino acid residue located from position 17 to position 25 of SEQ ID NO:2; or b) any amino acid residue located from a position equivalent to position 421 to a position equivalent to position 429 of SEQ ID NO: 2 and any amino acid residue located from a position equivalent to position 17 to a position equivalent to position 25 of SEQ ID NO: 2, after optimal global alignment with SEQ ID NO:2.Type: ApplicationFiled: March 16, 2020Publication date: May 26, 2022Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS SACLAYInventors: Aurélie ALBERTINI, Hélène RAUX, Yves GAUDIN, Franck PEREZ
-
Patent number: 11332566Abstract: Disclosed are novel polymers that contain monomer units derived from 4-vinylpyridine and monomer units derived from a co-monomer. The polymers may be complexed with a metal, and linear or crosslinked. Also disclosed are methods for preparing these polymers by radical polymerization, as well as to their use for metal capture in aqueous media, particularly uranium capture in seawater or in final nuclear waste from nuclear power plants.Type: GrantFiled: October 2, 2017Date of Patent: May 17, 2022Assignee: UNIVERSITE PARIS-SACLAYInventors: Philippe Gérard Roger, Mohamad Maaz, Bilal Nsouli, Tamara Elzein, Nadine Barroca-Aubry, Bénédicte Lepoittevin
-
Publication number: 20220143065Abstract: The present inventors have identified an miRNA capable of greatly modulating the inflammatory response induced by Clostridium difficile. They thus propose incorporating this miRNA into a pharmaceutical composition for preventing or reducing the harmful effects of this infection on the bowels of infected patients. This microRNA is miR-27a-5p. Advantageously, this miRNA can be linked to a matrix, incorporated into particles, or conveyed by a vector. It can be administered to infected subjects for therapeutic purposes.Type: ApplicationFiled: November 8, 2019Publication date: May 12, 2022Applicants: UNIVERSITE PARIS-SACLAY, ASSISTANCE PUBLIQUE - HOPITAUX DE PARISInventors: Imad KANSAU, Hussein KOBEISSY, Cecile LARRAZET, Jean-Christophe MARVAUD